Icosavax
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Icosavax was a Seattle clinical-stage biopharmaceutical company formed in 2017 to advance VLP (virus-like particle) technology from the University of Washington's Institute for Protein Design. It developed differentiated vaccines against infectious diseases, led by IVX-A12 — a Phase III-ready combination VLP vaccine targeting both RSV and human metapneumovirus (hMPV) in older adults — plus influenza and SARS-CoV-2 programs.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Icosavax was formed in 2017 to commercialize breakthrough VLP technology from the University of Washington's Institute for Protein Design.
- Series A
Icosavax launched with a $51 million Series A on October 3, 2019, led by Qiming Venture Partners USA.
- IPO
Icosavax closed its initial public offering in August 2021.
- Acquired by AstraZeneca
On February 19, 2024, AstraZeneca completed its acquisition of Icosavax — $15.00 per share in cash plus up to $5.00 per share in contingent value rights, a combined transaction value of about $1.1 billion — gaining the Phase III-ready IVX-A12 vaccine candidate.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.